Shots:
- The company’s Rybrevant + CT (carboplatin & pemetrexed) has gained the CHMP’s positive opinion as a 1L therapy for NSCLC associated with activating EGFR exon 20 insertion mutations
- The opinion was based on the P-III (PAPILLON) trial assessing the safety & efficacy of Rybrevant + CT vs CT in NSCLC patients (n=308) with EGFR exon 20 insertion mutations that showed improved PFS (1EP) & a trend favoring interim OS. 7% TRAEs leading to discontinuation
- Rybrevant is a bispecific Ab targeting activated & resistant EGFR mutation as well as MET mutations and amplifications
Ref:Johnson & Johnson | Image: Johnson & Johnson| Press Release
Related News:- Servier at SNO 2023: Dr. Susan Pandya Sheds Light on IDH-Mutant Diffuse Glioma Management
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
